A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Pfizer

Status and phase: Withdrawn; Phase 1

Conditions: Healthy

Treatments: Drug: PF-03382792 5 mg; Drug: PF-03382792 0.5mg; Drug: PF-03382792 15 mg; Drug: PF-03382792 1.5 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT01089738

B1651003

Details and patient eligibility

About

This study is designed to look at the safety and blood concentrations of PF-03382792 in healthy elderly subjects after taking multiple doses for 14 days.

Full description

To examine safety, toleratibilty and pharmacokinetics of PF-03382792 in healthy elderly subjects.

Sex: All

Ages: 65 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteer aged 65-80 years old
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2
• Total body weight >50 kg (110 lbs).

Exclusion criteria

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Subjects with symptoms or signs of adrenal insufficiency.
• Subjects with clinically significant ocular lens abnormalities as detected by the investigator based on the findings of a slit lamp examination performed by an ophthalmologist.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Double Blind

---

0 participants in 1 patient group

Dosing

Experimental group

Description:

Ascending Doses

Treatment:

Drug: PF-03382792 15 mg

Drug: PF-03382792 5 mg

Drug: PF-03382792 0.5mg

Drug: PF-03382792 1.5 mg